Italia markets close in 7 hours 16 minutes

Arbutus Biopharma Corporation (0SGC.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,9015-0,5005 (-20,84%)
Al 06:45PM BST. Mercato aperto.

Arbutus Biopharma Corporation

701 Veterans Circle
Warminster, PA 18974
United States
267 469 0914
https://www.arbutusbio.com

Settore/i
Settore
Impiegati a tempo pieno85

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. William H. CollierPres, CEO & Director1,03MN/D1960
Mr. David C. Hastings CPACFO & Chief Accounting Officer647,1kN/D1961
Dr. Michael J. Sofia Ph.D.Chief Scientific Officer670,22kN/D1958
Ms. Lisa M. CaperelliVP of Investor RelationsN/DN/DN/D
Dr. Elizabeth HowardExec. VP, Gen. Counsel, Chief Compliance Officer & Sec.N/DN/D1954
Dr. Gaston Picchio Ph.D.Chief Devel. OfficerN/DN/D1964
Mr. Michael J. McElhaughChief Bus. OfficerN/DN/D1975
Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C, Q.C.Sec.N/DN/D1951
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Governance aziendale

L'ISS Governance QualityScore di Arbutus Biopharma Corporation al 1 settembre 2022 è 6. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 5; diritti degli azionisti: 7; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.